A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Multiple Ascending Doses of ASP7962 in Healthy Subjects

NCT02136316 | Completed Phase 1

• 2 other identifiers: 7962-CL-00022014-000159-95
• Study Type: interventional
• Target: 48
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to evaluate the safety and tolerability as well as the pharmacokinetics of increasing oral multiple doses of ASP7962 in healthy young male and female subjects.

Conditions

Healthy Volunteers; Pharmacokinetics of ASP7962

Keywords

Healthy volunteers; ASP7962; pharmacokinetics

Outcome Measures

Primary Outcomes (9)

• Safety as assessed by adverse events

  up to end of study visit (29 days)

• Safety as assessed by vital signs

  up to end of study visit (29 days)

• Safety as assessed by orthostatic challenge test

  Day 1 and 16

• Safety as assessed by clinical laboratory tests

  up to end of study visit (29 days)

• Safety as assessed by electrocardiogram (ECG)

  Routine 12-lead ECG, continuous cardiac monitoring (Holter ECG) and real-time cardiac monitoring (ECG telemetry)

  up to end of study visit (29 days)

• Safety as assessed by Bond and Lader visual analogue scale (VAS)

  Day 3-19

• Safety as assessed by Addiction Research Center Inventory (ARCI)-49 (49-item)

  Day 3-19

• Safety as assessed by Columbia - Suicide Severity Rating Scale (C-SSRS)

  Day 2-19

• Safety as assessed by CogState cognitive test battery: Groton Maze Learning Task, Groton Maze Learning Task-Delayed Recall, Detection Task, Identification Task, One Card Learning Task, One Back Task

  Day 3-19

Secondary Outcomes (4)

• Pharmacokinetic profile of ASP7962 (plasma): AUC12, AUC12,u, AUCinf, AUCinf,u , AUClast, AUClast,u, CL/F, CLu/F, Cmax

  up to Day 19

• Pharmacokinetic profile of ASP7962 (plasma): Cmax,u, MRT, t1/2, tmax, tlag, λz, fu, AUCinf,u/AUCinf , Vz/F

  up to Day 19

• Pharmacokinetic profile of ASP7962 (plasma): Ctrough, AUCtau, Rac(AUC), Rac(Cmax), PTR, Ratio AUCu/AUC, Vz,u/F, AUCtau,u

  up to Day 19

• Pharmacokinetic profile of ASP7962 (urine): Aeinf, Aeinf%, Aelast, Aelast%, CLR, CLR,u, Aetau, Aetau%

  Day 1 and 16

Study Arms (4)

ASP7962 low dose

EXPERIMENTAL

Drug: ASP7962

ASP7962 medium dose

EXPERIMENTAL

Drug: ASP7962

ASP7962 high dose

EXPERIMENTAL

Drug: ASP7962

Placebo

PLACEBO COMPARATOR

Drug: Placebo

Interventions

ASP7962 DRUG

Oral

ASP7962 high dose; ASP7962 low dose; ASP7962 medium dose

Placebo DRUG

Oral

Placebo

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Subject has a body mass index of 18.5 - 30.0 kg/m2, inclusive. Subject weighs at least 50 kg.
• Female subject must be of non-childbearing potential:
• Postmenopausal (defined as at least 1 year without any menses and confirmation of FSH levels) prior to screening, or
• Documented surgically sterile or status post-hysterectomy (at least 1 month prior to screening).
• Male subject and their female spouse/partner who are of childbearing potential must be using 2 highly effective forms of birth control (1 of which must be a barrier method) starting at screening and continued throughout the clinical study period, and for 90 days after the final study drug administration.
• Male subject must not donate sperm starting at screening, throughout the clinical study period, and for 90 days after the final study drug administration.
• Subject agrees not to participate in another interventional study while participating in the present clinical study, defined as signing the informed consent form until completion of the last study visit.

You may not qualify if:

• Subject has a known or suspected hypersensitivity to ASP7962 or any components of the formulation used.
• Subject has a history of suicide attempt or suicidal behavior. Any suicidal ideation within the last 3 months.
• Subject has any of the liver function tests (aspartate aminotransferase \[AST\], alanine aminotransferase \[ALT\], alkaline phosphatase, gamma glutamyl transferase, total bilirubin \[TBL\]) above the upper limit of normal \[ULN\]. In such a case the assessment may be repeated once \[day -1\].
• Subject has any clinically significant history of allergic conditions.
• Subject has/had febrile illness or symptomatic, viral, bacterial (including upper respiratory infection), or fungal (non-cutaneous) infection within 1 week prior to admission to the clinical unit on day -1.
• Subject has a mean pulse rate \< 40 or \> 90 bpm; mean systolic blood pressure (SBP) \> 140 mmHg; mean diastolic blood pressure (DPB) \> 90 mmHg (vital sign measurements taken in triplicate after subject has been resting in supine position for 5 minutes; pulse rate will be measured automatically) \[day -1\]. If the mean pulse rate, mean SBP or mean DBP is out of the range as specified above, 1 additional triplicate measurement may be taken on day -1.
• Subject has a mean corrected QT interval using Fridericia's formula (QTcF) interval \> 430 ms (for male subjects) and \> 450 ms (for female subjects) on admission to the clinical unit on day 1. If the mean QTcF exceeds the limits above, 1 additional triplicate ECG can be taken \[day -1\].
• Subject uses any prescribed or non-prescribed drugs (including vitamins, natural and herbal remedies, e.g., St. John's wort) in the 2 weeks prior to study drug administration, except for occasional use of paracetamol (up to 2 g/day).
• Subject has used nicotine-containing products within 6 months prior to admission to the clinical unit.
• Subject has a history of drinking more than 21 units of alcohol per week for male subjects or 14 units of alcohol per week for female subjects (1 unit = 10 g pure alcohol = 250 mL of beer \[5%\] or 35 mL of spirits \[35%\] or 100 mL of wine \[12%\]) within 3 months prior to admission to the clinical unit.
• Subject uses any drugs of abuse within 3 months prior to admission to the clinical unit.
• Subject uses any inducer of metabolism (e.g., barbiturates, rifampin) in the 3 months prior to admission to the clinical unit.
• Subject has had a significant blood loss, donated 1 unit (500 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days or donated plasma within 7 days prior to admission to the clinical unit.
• Subject has a positive serology test for hepatitis B surface antigen, hepatitis A virus antibodies (immunoglobulin M), hepatitis C virus antibodies, or antibodies to human immunodeficiency virus type 1 (HIV-1) and/or type 2 (HIV-2) at screening.
• Subject has participated in any clinical study or has been treated with any investigational drugs within 28 days or 5 half-lives, whichever is longer, prior to screening.

Sponsors & Collaborators

• Astellas Pharma Europe B.V.: lead

Study Sites (1)

Site GB44001 Parexel Early Phase Clinical Unit

London, HA13UJ, United Kingdom

Location

Study Officials

• Medical Monitor

  Astellas Pharma Europe B.V.

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 9, 2014
• First Posted: May 13, 2014
• Study Start: May 1, 2014
• Primary Completion: November 1, 2015
• Study Completion: November 1, 2015
• Last Updated: December 15, 2015

Record last verified: 2015-12

Locations

GB (1)